CCO Treatment Updates

Treatment Options in Colon and Rectal Cancers: The Role of Oral Therapy

Update on the Use of Oral Therapies in Colon and Rectal Cancers

Module 1 of 1

Faculty:

David H. Ilson, MD, PhD
  • David H. Ilson, MD, PhD

CME CREDIT INFORMATION

Release Date: 11/05/07

Expiration Date: 11/04/08


Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Status: Please log in to view status
Begin the Module

David H. Ilson, MD, PhD, describes recent data on treatment approaches using oral agents in the management of colon and rectal cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe recent data on efficacy and toxicity of oral agents under investigation in colon and rectal cancers
  • Evaluate the results of trials using oral agents in combination with other cytotoxic therapies in colon and rectal cancer
  • Relate data on targeted agents being explored in combination with oral therapies for the treatment of colon and rectal cancers

Interactive Case Challenges

Management of a 65-Year-Old Male With Metastatic Colorectal Cancer and Gilbert's Syndrome

Faculty:

Alan P. Venook, MD
  • Alan P. Venook, MD

CME CREDIT INFORMATION

Release Date: 11/02/07

Expiration Date: 11/01/08


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status
Begin the Case Challenge

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Articulate the options for cytotoxic and targeted agents as first-line treatment of a patient with metastatic colorectal cancer and Gilbert’s syndrome
  • Describe the surgical considerations for primary tumors for a patient with metastatic colorectal cancer and Gilbert’s syndrome
  • Relate strategies for addressing treatment-induced neuropathy during administration of an oxaliplatin-based regimen for a patient with metastatic colorectal cancer and Gilbert’s syndrome

Treatment of a 62-Year-Old Male With Locally Advanced Rectal Cancer

Faculty:

John L. Marshall, MD
  • John L. Marshall, MD

CME CREDIT INFORMATION

Release Date: 11/13/07

Expiration Date: 11/12/08


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status
Begin the Case Challenge

John L. Marshall, MD, discusses strategies for pre- and postoperative management of a patient with locally advanced rectal cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Articulate the options for cytotoxic and targeted agents as first-line treatment of a patient with locally advanced rectal cancer
  • Describe the rationale for using neoadjuvant chemoradiation in a patient with locally advanced rectal cancer
  • Relate adjuvant treatment options for a patient with locally advanced rectal cancer

Adjuvant Treatment in a 74-Year-Old Male With Stage III Colorectal Cancer

Faculty:

Edward Chu, MD
  • Edward Chu, MD

CME CREDIT INFORMATION

Release Date: 11/16/07

Expiration Date: 11/15/08


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status
Begin the Case Challenge

Edward Chu, MD, discusses the appropriate approach for treating an older patient with stage III colorectal cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate adjuvant treatment strategies available for older patients with stage III colorectal cancer
  • Discuss management strategies for addressing toxicity associated with adjuvant chemotherapeutic agents in colorectal cancer
  • Describe the use of capecitabine in lieu of 5-fluorouracil/leucovorin in the treatment of stage III colorectal cancer and the rationale for its usage
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

This program is supported by an independent educational grant from Roche.